

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL

OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	▼ None	Entity Type
0001659323			Corporation
Name of Issuer			C Limited Partnership
Iterum Therapeutics Ltd			C Limited Liability Company
Jurisdiction of Incorporation/Organization			C General Partnership
IRELAND			C Business Trust
Year of Incorporation/Organiza	tion		€ Other
Over Five Years Ago			A company organized under the
Within Last Five Years (Specify Year)	2015		laws of Ireland.
O Yet to Be Formed			

2. Principal Place of Business and Contact Information						
Name of Issuer						
Iterum Therapeutics Ltd						
Street Address 1		Street Address 2				
25-28 NORTH WALL QUAY						
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer			
DUBLIN	IRELAND	D01 H104	(872) 225-6077			

3. Related Persons			
Last Name	First Name		Middle Name
Fishman	Corey		N.
Street Address 1		Street Address 2	
c/o Iterum Therapeutics Limite	d	25-28 North Wal	l Quay
City	State/Province/C	Country	ZIP/Postal Code
Dublin	IRELAND		D01 H104
Relationship: Exec	cutive Officer	☑ Director	Promoter
Clarification of Response (if Necessa	urv)		
Carmenton of response (if recesse			
Total Norma	First Name		M'III. N
Last Name			Middle Name
Heron	Patrick		J.
Street Address 1		Street Address 2	
c/o Iterum Therapeutics Limite	d	25-28 North Wal	l Quay
City	State/Province/C	Country	ZIP/Postal Code
Dublin	IRELAND		D01 H104
Relationship: Exec	cutive Officer	Director	Promoter

Clarification of Response (if Nec	essary)			
ast Name	First Name		Middle Name	
Hunt	Ronald		M.	
treet Address 1		Street Address 2		
c/o Iterum Therapeutics Lin		25-28 North V		
City	State/Province	e/Country	ZIP/Postal Code	
Dublin	IRELAND		D01 H104	
Relationship:	Executive Officer	☑ Director	Promoter	
Clarification of Response (if Nec	essary)			
ast Name	First Name		Middle Name	
Ahrens	Brenton		K.	
treet Address 1		Street Address 2	2	
c/o Iterum Therapeutics Lin	nited	25-28 North V	Vall Quay	
City	State/Province	e/Country	ZIP/Postal Code	
Dublin	IRELAND		D01 H104	
Relationship:	Executive Officer	☑ Director	Promoter	
Clarification of Response (if Nec				
ast Name	First Name		Middle Name	
Healy	James		I.	
treet Address 1		Street Address 2	2	
c/o Iterum Therapeutics Lin	nited	25-28 North V	Vall Quay	
City	State/Province	e/Country	ZIP/Postal Code	
Dublin	IRELAND		D01 H104	
Relationship:	Executive Officer	☑ Director	Promoter	
Clarification of Response (if Nec	occoru)			
trainication of Response (if Nec	essai y)			
Last Name	First Name		Middle Name	
Edick	Paul		R.	
treet Address 1	1 <u>(</u>	Street Address 2		
c/o Iterum Therapeutics Lin	nited	25-28 North V		
City	State/Province		ZIP/Postal Code	
Dublin	IRELAND	*	D01 H104	
			<u> </u>	
Relationship:	Executive Officer	Director	Promoter	
		The second secon		
Clarification of Response (if Nec	essary)			

Last Name		First Name			Middle	Name	
Dunne		Michael			w.		\neg
Street Address 1			6	Street Address 2			_
c/o Iterum Therapeut	ics Limited			25-28 North Wa	ll Quay		
City		State/Province/	Coun	try	ZIP/Po	stal Code	
Dublin		IRELAND			D01 F	H104	\neg
		1		•			
Relationship:	Execut	ive Officer	П	Director		Promoter	
Clarification of Response	(if Necessary)					_
							\equiv
Last Name		First Name			Middle	Name	
Matthews		Judith			M.		\neg
Street Address 1				Street Address 2			
c/o Iterum Therapeut	ics Limited			25-28 North Wa	ll Quay		1
City		State/Province/	Coun			stal Code	1
Dublin		IRELAND	Coun		D01 F		$\overline{}$
Dubin		IKELAND			Doll	1104	
Relationship:	Execut	ive Officer	Г	Director		▼ Promoter	\neg
Relationship.	Execut	- Ive Officer	L			1 Tomoter	
Clarification of Response	(if Necessary)					
Last Name		First Name			Middle	Name	
Kelly		David			I.		
Street Address 1			5	Street Address 2	-		
c/o Iterum Therapeutics Limited 25-28 North Wall Quay							
City		State/Province/	Coun	try	ZIP/Po	stal Code	
Dublin		IRELAND			D01 F	H104	
Relationship:	Execut	ive Officer	V	Director		Promoter	
Clarification of Response	(if Necessarv)					
		-					$\overline{}$

4. Industry Group

Agriculture Banking & Financial Services C Commercial Banking C Insurance C Investing C Investment Banking C Pooled Investment Fund Other Banking & Financial C Services C Business Services Energy C Coal Mining C Electric Utilities C Energy Conservation	Health Care Biotechnology C Health Insurance C Hospitals & Physicians C Pharmaceuticals C Other Health Care C Telecommunications C Other Technology Travel C Manufacturing Real Estate C Commercial C Construction C REITS & Finance C Residential C Other Real Estate C Other C Other C Residential C Other C Other C Retailing C Restaurants C Computers C Computers C Airlines & Airports C Lodging & Conventions C Tourism & Travel Services C Other Travel C Other C Other
© Environmental Services © Oil & Gas © Other Energy 5. Issuer Size	
	Aggregate Net Asset Value Range
Revenue Range O No Revenues	No Aggregate Net Asset Value No Aggregate Net Asset Value
C \$1 - \$1,000,000	S1 - \$5,000,000
C \$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	© \$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	C \$50,000,001 - \$100,000,000
C Over \$100,000,000	Over \$100,000,000
© Decline to Disclose	C Decline to Disclose
C Not Applicable	C Not Applicable
6. Federal Exemption(s) apply)	and Exclusion(s) Claimed (select all that
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
Rule 504 (b)(1)(i)	☑ Rule 506(b)
Rule 504 (b)(1)(ii)	
Rule 504 (b)(1)(iii)	Rule 506(c)
1 Kuit 504 (D)(1)(III)	Securities Act Section 4(a)(5)
	Investment Company Act Section 3(c)
7. Type of Filing	
П	2015 11 19 First Sala Vot to Occur
New Notice Date of First Sale	2015-11-18 First Sale Yet to Occur
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to last	t more than one year?
— Pooled Investment Fund	Offered (select all that apply)

Tena	nt-in-Common Securities	☐ Debt			
Mine	eral Property Securities		arrant or Other Right to nother Security		
Exer	rity to be Acquired Upon cise of Option, Warrant or r Right to Acquire rity	Other (desc	cribe)		
10. Bu	usiness Combina	ation Tran	saction		
Is this offe	ering being made in connect n, such as a merger, acquis	ion with a busine	ess combination C v	es No	
	ion of Response (if Necessar				
11. M	inimum Investm	ent			
Minimum investor	investment accepted from	any outside \$	0	USD	
	ales Compensati	on			
Recipient			Recipient CRD Num	ber None	
		20.00	(Associated) Broke	r or Doulor CDD	
(Associate	ed) Broker or Dealer	None	Number	No.	one
Street Ac	ddress 1		Street Address 2		
City		Si	tate/Province/Country	ZIP/Postal Coo	le le
State(s) of	f Solicitation		□ All States		
12 0	fforing and Cala	Amount			
13.0	ffering and Sales	Amounts			
Total Offe	ering Amount \$ 4764000	00	USD 🗆 Indefinite		
Total Amo	ount Sold \$ 4763999	19	USD		
Total Rem Sold	naining to be \$ 1		USD Indefinite		
Clarificati	ion of Response (if Necessar	y)			
11 lp	vootoro				
14. 10	vestors				
	Salaat if saanwities in the off	oving hove been	on may be sald to newsons	who I	
	Select if securities in the off do not qualify as accredited Number of such non-accred offering	investors,			
	Regardless of whether secu to persons who do not qual number of investors who al	fy as accredited i	investors, enter the total	old 13	

15. Sales Commissions & Finders' Fees Expenses

Sales Commissions	0	USD	Estimate
Finders' Fees	\$ 0	USD	Estimate
Clarification of Response (if Necessar	y)		

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0	USD	Estimat
	-	

Clarification of Response (if Necessary)

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Iterum Therapeutics Ltd	/s/ Corey Fishman	Corey Fishman	President	2016-12-30